1. Introduction {#sec1-ijms-19-03322}
===============

Articular cartilage lesions occurring after traumatic injury or during progressive osteoarthritis (OA) represent a major problem in orthopedic surgery as this specialized tissue has a limited intrinsic capability for self-regeneration in absence of vascularization that may deliver reparative progenitor cells \[[@B1-ijms-19-03322],[@B2-ijms-19-03322]\]. Thus far, none of the available clinical options, from conservative treatments to surgical approaches to restore the entire osteochondral region \[[@B3-ijms-19-03322],[@B4-ijms-19-03322]\], have been capable of reliably and definitely allowing for the reproduction of the original hyaline cartilage in sites of damage \[[@B5-ijms-19-03322],[@B6-ijms-19-03322]\] with a typical extracellular matrix (ECM) deposition, zonal organization, and native chondrocyte cellular phenotype that may permit functional biomechanical performance \[[@B7-ijms-19-03322],[@B8-ijms-19-03322]\].

In this regard, stem cell-based therapy is considered to be a promising approach to treat cartilage lesions as administration of such cells in sites of injury may provide a reparative population with strong potential to commit towards the chondrocyte phenotype versus the chondrocytes themselves that tend to lose their phenotype upon expansion \[[@B9-ijms-19-03322]\]. Mesenchymal stromal cells (MSCs) are especially good candidates to achieve this goal as they are capable of undergoing commitment events that lead to the formation of mesodermal tissues (cartilage, bone, muscle, marrow stoma, tendon, fat, dermis, connective tissues) \[[@B10-ijms-19-03322],[@B11-ijms-19-03322],[@B12-ijms-19-03322]\] while displaying trophic, homing, and immunomodulatory activities for cells of the surrounding cartilage \[[@B13-ijms-19-03322],[@B14-ijms-19-03322],[@B15-ijms-19-03322]\]. The following minimal set of standard criteria for characterization of MSCs have been provided by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy: plastic-adherence in standard culture conditions, expression of CD105, CD73, and CD90 and lack of surface expression of CD45, CD34, CD14 (CD11b), CD79α (CD19), and HLA-DR, and reliable and safe potential for differentiation mesodermal lineages (chondrocytes, osteoblasts, adipocytes) under defined culture conditions \[[@B16-ijms-19-03322],[@B17-ijms-19-03322]\] for instance compared with embryonic stem cells (ESCs) \[[@B18-ijms-19-03322]\] and induced pluripotent stem cells (iPSCs) \[[@B19-ijms-19-03322]\] that carry a risk for teratoma formation and tumorigenesis \[[@B20-ijms-19-03322],[@B21-ijms-19-03322]\]. MSCs have been isolated from a variety of tissues including the bone marrow, adipose tissue, synovium, perichondrium and periosteum, trabecular bone, umbilical cord blood, amniotic fluid, Wharton's jelly, skeletal muscle, and even peripheral blood, all showing---at a different extent---a potential to commit towards mesodermal cells \[[@B19-ijms-19-03322],[@B22-ijms-19-03322],[@B23-ijms-19-03322],[@B24-ijms-19-03322],[@B25-ijms-19-03322],[@B26-ijms-19-03322],[@B27-ijms-19-03322]\].

Due to the regenerative (and immunomodulatory) properties and mechanisms of action of MSCs, and considering the suboptimal results in targeting only focal lesions, a recent, increasing interest in the manipulation of MSCs in injectable approaches in order to modulate the entire joint \[[@B28-ijms-19-03322]\]. Clinical benefits have been reported regardless of the cell source, indication, or administration method \[[@B28-ijms-19-03322],[@B29-ijms-19-03322],[@B30-ijms-19-03322],[@B31-ijms-19-03322]\]. Still, the efficacy of the cell injection procedure may be impaired by cell manipulation and damage, as well as dissemination to non-target tissues \[[@B32-ijms-19-03322],[@B33-ijms-19-03322]\]. To circumvent such issues, stem cell delivery may be performed using injectable vehicles as a containment system that may also provide a favorable cell microenvironment \[[@B34-ijms-19-03322]\]. As a matter of fact, a recent study published by Desando et al. showed that the combination of MSCs with a vehicle such as hyaluronic acid (HA) modulated cell homing while promoting their attachment and integration within the damaged articular cartilage \[[@B34-ijms-19-03322]\]. Injectable stem cell carriers that may be used for translational and clinical applications include platelet-rich plasma (PRP), platelet concentrate, HA, and a variety of hydrogel systems.

The aim of this systematic review was to analyze the available evidence on the clinical application of PRP, HA, and hydrogels for the delivery of MSCs, together with an analysis of preclinical studies that support the rationale for their use to shed light and give indications on what can be expected with such MSC-based injectable systems for the treatment of cartilage lesions and joint degeneration.

2. Results {#sec2-ijms-19-03322}
==========

According to the search strategy, 876 papers from Web of Science and 843 papers from PubMed were screened of which 41 met the inclusion criteria ([Figure 1](#ijms-19-03322-f001){ref-type="fig"}). After full text screening, one further article was excluded since it was a clinical protocol description without any specifications on treatment results. Nineteen are preclinical papers ([Table 1](#ijms-19-03322-t001){ref-type="table"}) and 21 clinical papers ([Table 2](#ijms-19-03322-t002){ref-type="table"}). While the overall results of the literature search are summarized in the following paragraphs, further study details have been reported in [Table 1](#ijms-19-03322-t001){ref-type="table"} and [Table 2](#ijms-19-03322-t002){ref-type="table"} for preclinical and clinical studies, respectively.

2.1. Preclinical Studies {#sec2dot1-ijms-19-03322}
------------------------

Proof-of-concept of providing regenerative MSCs via injectable carriers in vivo has been demonstrated in several preclinical animal models both of focal defects and OA. In particular, five papers reported on MSCs combined with PRP for degenerative joint disease, 12 with HA (4 for osteochondral treatment and 8 for OA), and two with hydrogels (for OA) ([Table 1](#ijms-19-03322-t001){ref-type="table"}). Overall, these studies all supported the use of MSCs with PRP, HA, or hydrogel combination, with positive findings in both focal and degenerative joint lesions.

### 2.1.1. MSC Injection with PRP {#sec2dot1dot1-ijms-19-03322}

PRP was employed to deliver bone marrow- and fat-derived isolated or concentrated MSCs to treat degenerative joint disease in horse models, which revealed improvements in the functionality and sustainability of the damaged joints compared with PRP alone \[[@B35-ijms-19-03322]\] as well as in the lameness score without adverse events \[[@B36-ijms-19-03322]\]. PRP was also applied to smaller animal models of OA as a carrier of muscle- and adipose tissue-derived MSCs (also upon genetic modification), leading to improved cartilage repair versus administration of cells alone in rats \[[@B37-ijms-19-03322]\] and rabbits \[[@B38-ijms-19-03322]\], and to decreased lameness and inflammation with enhanced focal compressive strength relative to control treatments in dogs \[[@B39-ijms-19-03322]\]. Overall, three \[[@B35-ijms-19-03322],[@B37-ijms-19-03322],[@B39-ijms-19-03322]\] out of these studies directly compared the use of MSCs with or without PRP, and among them, two were able to demonstrate the benefit of using the cell carrier combination with respect to MSCs alone.

### 2.1.2. MSC Injection with HA {#sec2dot1dot2-ijms-19-03322}

HA has also been employed to inject bone marrow-derived MSCs in focal defects, promoting enhanced cartilage repair in minipigs \[[@B40-ijms-19-03322]\], goats \[[@B41-ijms-19-03322]\], horses \[[@B42-ijms-19-03322]\], and rabbits \[[@B43-ijms-19-03322]\] relative to control treatments including HA alone or cells without HA. Similarly, improved cartilage repair and reduced disease progression and inflammation were documented in animal models of OA treated with HA and bone marrow- or adipose tissue-derived MSCs in goats and sheep \[[@B44-ijms-19-03322],[@B45-ijms-19-03322],[@B46-ijms-19-03322]\], donkeys \[[@B47-ijms-19-03322]\], pigs \[[@B48-ijms-19-03322]\], rabbits \[[@B34-ijms-19-03322],[@B49-ijms-19-03322]\], and rats \[[@B50-ijms-19-03322]\] versus HA alone or cells without HA. Overall, only four \[[@B34-ijms-19-03322],[@B43-ijms-19-03322],[@B48-ijms-19-03322],[@B50-ijms-19-03322]\] out of these studies directly compared the use of MSCs with or without HA, and among these, three demonstrated the benefits of using the cell carrier combination with respect to MSCs alone, while one study described better results in counteracting OA progression using MSCs and HA alone compared with their combination \[[@B50-ijms-19-03322]\].

### 2.1.3. MSC Injection with Hydrogels {#sec2dot1dot3-ijms-19-03322}

Hydrogels were also created to deliver bone marrow-derived MSCs to treat OA in rats based on self-assembling peptide hydrogels, leading to reduced inflammation and cell apoptosis as well as chondroprotection and cartilage repair \[[@B51-ijms-19-03322],[@B52-ijms-19-03322]\] relative to control groups without cells or HA. In particular, one \[[@B52-ijms-19-03322]\] of these studies directly compared the use of MSCs with or without hydrogel, demonstrating the benefit of using the cell carrier combination with respect to MSCs alone.

2.2. Clinical Studies {#sec2dot2-ijms-19-03322}
---------------------

A number of clinical protocols were established using injectable carriers of MSCs to treat cartilage lesions and OA degeneration in patients, with a total of 21 papers meeting the inclusion criteria: 13 combined MSCs with PRP (one for osteochondral lesions and 12 for OA), four with HA (three for osteochondral lesions and one for OA), and four with a combination of PRP and HA (all for OA) ([Table 2](#ijms-19-03322-t002){ref-type="table"}).

### 2.2.1. MSC Injection with PRP {#sec2dot2dot1-ijms-19-03322}

With regards to PRP cell delivery, three papers reported randomized clinical trials (RCT), three comparative studies, 7 case series, and one case report. Of these papers, 10 applied SVF (stromal vascular fraction) as a cell source, one cultured BMSCs, and two bone marrow aspirate concentrate (BMAC). RCT and comparative studies have been described while case series and case reports results have been summarized in the following paragraphs (details have been reported in [Table 2](#ijms-19-03322-t002){ref-type="table"}).

As per RCT, both papers focused on OA. More in detail, in 2014 Koh et al. \[[@B62-ijms-19-03322]\] reported on 44 patients with knee OA who underwent high tibial osteotomy followed by either PRP injection or PRP plus SVF injection, describing the best performance in pain relief and symptoms improvement in the cell group after 24 months. More recently, in 2017 Shapiro et al. \[[@B57-ijms-19-03322]\] performed a study on 25 patients with bilateral knee OA, where the two knees were randomized into injection saline or BMAC in combination with another blood derivative (platelet-poor plasma) and followed for up to six months. Early results showed that BMAC was a safe, reliable, and viable cellular product, but study patients experienced the same relief of pain in both BMAC- and saline-treated OA knees. Similarly, in 2018 Bastos et al. \[[@B54-ijms-19-03322]\] showed that cultured BMSCs in combination or not with PRP provided clinical improvement in patients with knee OA up to 12 months, without significant differences between groups.

The comparative studies focused on both osteochondral lesions \[[@B53-ijms-19-03322]\] and OA \[[@B63-ijms-19-03322],[@B65-ijms-19-03322]\]. With regard to osteochondral lesions, in 2015 Kim et al. \[[@B53-ijms-19-03322]\] compared the outcomes of combining SVF and PRP injection versus the implantation of SVF on fibrin glue for the treatment of full-thickness lesions of the knee. Describing the improvement in both groups at final follow up (28.6 months), greater cartilage regeneration (at second-look arthroscopic, 12.4 months post-treatment) and clinical outcome improvements occurred in the implantation group rather than in those receiving a SVF injection with PRP. With regard to OA studies, in 2012 and 2013, two studies have been performed by Koh et al. \[[@B65-ijms-19-03322]\] and Kim et al. \[[@B63-ijms-19-03322]\] comparing surgical techniques for OA (debridement or microfracture, respectively) in combination or not with injectable therapies (SVF+PRP). Higher clinical improvements were noted at final follow-up in both studies (16.4 months and 21.8 months, respectively) for the SVF+PRP group, in particular in patients under 55 years and with an OA degree below three \[[@B65-ijms-19-03322]\].

Case series and case reports all focused-on OA. All papers evidenced good results combining cells and PRP in terms of functional improvement and pain relief \[[@B55-ijms-19-03322],[@B56-ijms-19-03322],[@B58-ijms-19-03322],[@B59-ijms-19-03322],[@B60-ijms-19-03322],[@B61-ijms-19-03322],[@B64-ijms-19-03322]\] together with an improvement or maintenance of cartilage appearance at second-look arthroscopy \[[@B60-ijms-19-03322]\]. Magnetic resonance imaging (MRI) analysis showed better results with respect to the basal level in three papers \[[@B54-ijms-19-03322],[@B57-ijms-19-03322],[@B62-ijms-19-03322]\] while Pintat et al. \[[@B56-ijms-19-03322]\] described no complications and functional improvement but no relevant changes at MRI. Interesting, Bansal et al. \[[@B55-ijms-19-03322]\] showed no changes in hematological and biochemical parameters before and after treatment, and a reduction of atypical cells in the synovial fluid at 24 months with respect to the basal value. Out of these studies, no one presented a control group with MSCs only, thus clear conclusions on the benefit of the carrier were not obtained.

### 2.2.2. MSC Injection with HA {#sec2dot2dot2-ijms-19-03322}

Three papers \[[@B66-ijms-19-03322],[@B67-ijms-19-03322],[@B68-ijms-19-03322]\] reported the results of cells and HA combination on an osteochondral lesion treatment: one RCT, one comparative, and one case series where two used peripheral blood progenitor cells (PBPCs) and one used cultured bone marrow-derived MSCs. In 2013 Saw et al. \[[@B66-ijms-19-03322]\] randomized 50 patients into two treatments: subchondral drilling and peripheral blood progenitor cells (PBPCs)+HA injections versus HA alone. PBPCs+HA resulted in better improvement of articular cartilage quality as shown by histological and MRI analyses with respect to HA alone. The non-randomized comparative study was published in 2012 by Lee et al. \[[@B67-ijms-19-03322]\], who treated 70 patients affected by symptomatic cartilage defects with arthroscopic microfracture and intra-articular injection of cultured bone marrow-derived MSCs plus HA versus cultured bone marrow-derived MSCs and a periosteal patch implanted with an open technique. Both groups showed a similar clinical score improvement with the advantages of a minimally invasive approach for the arthroscopic technique.

The only RCT for the treatment of OA lesions was shown by Wong et al. in 2013 \[[@B69-ijms-19-03322]\], who described the effect of cultured BMSCs in combination with HA in patients who underwent microfracture and high tibial osteotomy (HTO) with better clinical and radiographic improvement with respect to HA alone \[[@B69-ijms-19-03322]\].

Also, the only case series \[[@B68-ijms-19-03322]\] in this group reported good results combining subchondral drilling with PBPCs and HA injections for the treatment of chondral lesions. Out of these studies, no one presented a control group with MSCs only, thus not allowing to draw a clear conclusion on the benefit of the carrier.

### 2.2.3. MSC Injection with PRP and HA {#sec2dot2dot3-ijms-19-03322}

Finally, four papers described the results of cell/HA/PRP combination for the treatment of OA, including one RCT \[[@B70-ijms-19-03322]\] and three case series \[[@B71-ijms-19-03322],[@B72-ijms-19-03322],[@B73-ijms-19-03322]\]. Recently in 2017, Turajane et al. \[[@B70-ijms-19-03322]\] described the use of autologous peripheral blood stem cells (AAPBSCs) in combination with PRP, hGCSF (human granulocyte colony-stimulating factor) and HA for the treatment of knee OA. Sixty patients were randomized into three groups: microfracture followed by injection of AAPBSCs, HA, and a mix of PRP+hGCSF or AAPBSCs, HA, and PRP versus HA injection alone. The results revealed the superiority of both AAPBSCs groups with respect to HA alone at 12 months in terms of total knee arthroplasty (TKA) avoidance and symptoms alleviation. The case series of Pak et al. \[[@B71-ijms-19-03322],[@B72-ijms-19-03322],[@B73-ijms-19-03322]\] reported overall good clinical results for SVF plus PRP plus HA injection for the treatment of knee OA, also from the radiological point of view with cartilage-like tissue regeneration \[[@B71-ijms-19-03322]\]. Out of these studies, no one presented a control group with MSCs only, thus clear conclusions on the benefit of the carrier were not obtained.

3. Discussion {#sec3-ijms-19-03322}
=============

This systematic research showed that MSC delivery with injectable systems (i.e., PRP, HA, hydrogels) appears to be a safe and promising treatment option with positive preclinical findings and early satisfying results in the clinical settings, although it is still not possible to draw conclusions on the entity of the added benefit of the delivery vehicle.

One of the most common solutions for an injectable system for MSCs is PRP, a blood derivative with a higher platelet concentration than whole blood. When activated, platelets release a group of biologically active proteins that bind to the transmembrane receptors of their target cells, thus leading to the expression of gene sequences that ultimately promote cellular recruitment, growth, and morphogenesis, and modulating inflammation as well \[[@B74-ijms-19-03322]\]. This led to the wide use of PRP, showing promising results as a minimally invasive injectable treatment of cartilage degeneration and OA both in preclinical and clinical studies \[[@B75-ijms-19-03322]\]. Among conservative treatments, viscosupplementation with HA has been also largely applied in clinical practice \[[@B3-ijms-19-03322],[@B76-ijms-19-03322]\]. HA is a non-sulfated glycosaminoglycan (GAG) in cartilaginous ECM maintaining chondrocyte functions and a component of synovial fluid responsible for its viscoelasticy \[[@B3-ijms-19-03322]\]. In vitro studies revealed that HA modulates inflammation inhibiting matrix metalloproteinases (MMPs) \[[@B77-ijms-19-03322]\]. HA has potential biological effects, including the enhancement of the chondrogenic effects of MSCs \[[@B78-ijms-19-03322]\] and the promotion of synovial cell or chondrocyte migration in the presence of basic fibroblast growth factors \[[@B79-ijms-19-03322]\]. Finally, hydrogels derived from natural tissues are interesting recent candidates as MSC delivery agents, allowing for the invasion of cells and subsequent matrix deposition \[[@B80-ijms-19-03322]\] with MSCs being capable of forming a cartilage specific matrix in three-dimensional hydrogel systems \[[@B80-ijms-19-03322],[@B81-ijms-19-03322]\].

The overall positive findings explain the interest in this therapeutic strategy, with more than half of the papers published in the last four years (22/40). In particular, MSCs and PRP in combination showed positive results in preclinical settings in the animal model of both focal and degenerative joint lesions in terms of a functional improvement and decrease of inflammation and lameness, resulting in the best approach with respect to MSCs or PRP alone as supported by several in vitro studies confirming the rational of combining MSCs and PRP stimulation to induce chondrogenic differentiation with upregulation of type-II collagen genes and other articular genes (as aggrecan, Sox9, ...) \[[@B82-ijms-19-03322],[@B83-ijms-19-03322]\]. MSCs play a key role in the response to tissue injuries not only by differentiating themselves but also by inducing regenerative processes and immunomodulatory changes in the joint homeostasis through the secretion of several bioactive molecules (as anti-apoptotic, anti-inflammatory, anti-scarring/anti-fibrosis molecules) \[[@B84-ijms-19-03322]\]. Similarly, PRP can influence all joint tissues, offering the possibility to deliver a high concentration of autologous growth factors and bioactive molecules in physiologic proportions that are critical to regulate tissue healing processes and modulate inflammation \[[@B75-ijms-19-03322]\]. Thus, the possibility to use these products in combination for an injection approach may further enhance the healing processes with respect to both biological products. Overall positive results were obtained upon intra-articular delivery of MSCs/PRP and in all papers their combined use can be consider safe as no major adverse events related to the treatment were reported. Bansal et al. \[[@B55-ijms-19-03322]\] performed a synovial fluid analysis from patients undergoing PRP+MSC treatment, showing a reduction of atypical cells after treatment and no abnormalities in hematological and biochemical parameters before and after 24 months of treatment.

Similarly, in MSCs and HA combination, preclinical results are overall positive in both animal models of focal and degenerative lesions, in particular in terms of the reduction of inflammation and disease progression \[[@B34-ijms-19-03322],[@B44-ijms-19-03322],[@B45-ijms-19-03322],[@B46-ijms-19-03322],[@B47-ijms-19-03322],[@B48-ijms-19-03322],[@B49-ijms-19-03322]\]. In the clinical settings, all papers described the treatment of osteochondral lesions, showing safety and positive results and the regeneration of hyaline-like cartilage over the same protocol without cells \[[@B66-ijms-19-03322]\]. A study by Lee et al. \[[@B67-ijms-19-03322]\] described similar results between the surgical and injection approach, with the advantage of intra-articular injection being minimally invasive. For the treatment of degenerative lesions, only RCT \[[@B69-ijms-19-03322]\] reported clinical and radiographic improvement in cells group with respect to HA alone, although the lack of cells in the alone group prevented useful information on the MSC carrier from being obtained.

The use of hydrogels as agents for MSC delivery was only described in the preclinical setting for OA treatment, showing good results in terms of improved cartilage regeneration and decrease in inflammation scores. Hydrogels are gaining attention as ECM mimicry systems due to their water content and water-swollen networks that facilitate the transport of water-soluble biomolecules \[[@B85-ijms-19-03322]\]. Such a treatment approach is still in early development and not yet translatable into a clinical protocol, as there is no current material capable of addressing all the mechanical challenges of injection approach \[[@B85-ijms-19-03322]\], and some further aspects need to be clarified including proper hydrogel viscosity, cells concentration, and application protocol.

Another interesting approach applied only in the clinical setting is the combination of both PRP and HA for MSC delivery. The use of HA in combination with PRP for OA treatment is gaining increasing attention in the scientific community, both in the preclinical and clinical settings, reporting overall good results in terms of anti-inflammatory effects \[[@B86-ijms-19-03322],[@B87-ijms-19-03322]\] and pain and function improvement \[[@B88-ijms-19-03322]\]. The rationale to combine these treatments systems as a carrier is related to their dissimilar biological mechanisms and to the rheological properties of HA which, together with the regenerative potential of PRP and MSCs, which might lead to a more effective treatment for OA \[[@B89-ijms-19-03322]\].

Finally, this systematic review also underlined another interesting finding. While in the preclinical papers expanded cells from different sources have been commonly used, in the clinical papers the main cell type and source used is the minimum manipulated SVF from the adipose tissue, probably due to the ease of collection and to economical, ethical, and regulatory issues \[[@B28-ijms-19-03322]\]. To date, there is no clear evidence about the most suited source of MSCs for joint tissues regeneration, the best procedure to obtain them, and the optimal cells dosage. The heterogeneous results presented in this systematic review actually confirm the confounding background and it is difficult to draw a clear conclusion on the best processing methods, MSC type and dosage, and their effect on joint tissues regeneration. Moreover, another unclear aspect is the composition of products for intra-articular injection in terms of cell number and type, when the MSCs are used as a concentrate \[[@B28-ijms-19-03322]\]. Regardless of the products injected, overall promising results were noted when combining MSCs with agents for joint delivery, but the real potential of these options needs to be confirmed by high quality comparative clinical studies with wider patient population, extended periods of evaluation, investigating also the proper cell dosage and source to be delivered. In fact, while there is some preclinical evidence with comparative studies showing the importance of delivery systems, the clinical literature is lacking specific treatment groups to identify their contributions to the outcomes, which makes their clinical usefulness questionable considering that overall good results have also been reported in clinical studies upon injection of MSCs without vehicles \[[@B28-ijms-19-03322]\]. Further comparative studies will thus be needed in the future to confirm the role of injectable systems and to optimize their function in clinical practice. Finally, the effect of such vehicles will have to be compared with the new frontiers of MSC delivery: in fact, current research is exploring the potential to improve MSC treatment by retaining them in target tissues long enough to induce the regeneration process through modern techniques of MSC magnetic labelling with an external device to permit cell localization in a specific area as reported by Kamei et al. \[[@B90-ijms-19-03322]\].

This systematic review of the literature revealed several limitations, such as the heterogeneity of both preclinical and clinical papers characterized by different delivery approaches, anatomical locations, animal model, and small patient population, which makes it difficult to draw any final conclusion about the best treatment strategy for the treatment of focal and degenerative cartilage lesions. Moreover, another key weakness is the study designs, which mainly focused on the combined use while rarely comparing groups to demonstrate the benefit of adding an MSC vehicle for injections.

Specific studies should be designed to demonstrate the improvement provided by injectable systems to deliver MSCs, as well as to identify the optimal source of cells (both in terms of ease of collection and cost-effectiveness, as well as differentiation potential and resistance-responsiveness to the inflammatory OA environment), their manipulation, dosage, the indications on pathology, and the disease phase with the aim of optimizing the outcome for a treatment of focal osteochondral lesions or joint degeneration.

4. Materials and Methods {#sec4-ijms-19-03322}
========================

The systematic literature search was performed using the PubMed and Web of Science databases with the following string: "(stem cells injection) AND (platelet rich plasma OR PRP OR platelet concentrate OR biomaterials OR hyaluronic acid OR hydrogels)", selecting papers in the English language published up to August of 2018 on the use of MSCs in combination with PRP, HA, or hydrogel injectable vehicles for joint delivery in the preclinical (in vivo) and clinical field for the treatment of cartilage pathology (focal defects or OA). Articles were first screened by title and abstract by two independent observers, subsequently, the full texts of the resulting articles were analyzed. Reference lists from the selected papers were also screened to identify further articles ([Figure 2](#ijms-19-03322-f002){ref-type="fig"}).

5. Conclusions {#sec5-ijms-19-03322}
==============

This systematic review revealed an increasing interest on the use of injectable agents for MSC delivery. While negligible adverse events and promising clinical outcomes were generally reported, the prevalence of low quality studies hinders the possibility to demonstrate the real benefits provided by combining MSCs with injectable systems. Many variables also need to be envisaged, such as most effective delivery agents, cell source, dosage, and most suitable application protocol. Finally, it will be important to identify which patients may benefit more from these procedures, before a wide application of this promising biological approach can occur in clinical practice for the treatment of cartilage lesions and OA degeneration.
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ijms-19-03322-t001_Table 1

###### 

Details of preclinical papers identified in the systematic research.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication                                 Animal Model   Lesion Type                         MSC Type                                                Delivery System                                                                                                 Study Design                                                                                                                                                                                                                                                     Results
  ------------------------------------------- -------------- ----------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **PRP**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Bembo 2016 \[[@B36-ijms-19-03322]\]\        Sport horses   OA                                  Micro fat suspension                                    PRP\                                                                                                            Micro fat+PRP\                                                                                                                                                                                                                                                   Significant improvement of the lameness score 3 months after treatment; returned to competition for 4 horses which 3 resumed intensive training; no adverse events
  Muscles, ligaments and tendon J                                                                                                                        Plts 4.3 ± 1.1 × 10^9^/L\                                                                                       Experimental time: 3 months                                                                                                                                                                                                                                      
                                                                                                                                                         Activation: No\                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                         Leucocytes: 20 ± 9 × 10^6^/L                                                                                                                                                                                                                                                                                                                                                     

  Broeckx 2014 \[[@B35-ijms-19-03322]\]\      Sport horses   Allogeneic PBMSCs                   PRP\                                                    PRP vs. MSCs vs. MSCs+PRP vs. chondrogenic induced MSCs+PRP\                                                    Significant function improvement up to 12 months after treatment in MSCs+PRP group compared with PRP alone. Highest short-term clinical scores were obtained with chondrogenic induced MSCs+PRP                                                                  
  PLoS ONE                                                                                       Plts 200 × 10^6^; stored at −80 °C before use\          Experimental time: 6 and 12 weeks, 6 and 12 months                                                                                                                                                                                                                                                                                                                               
                                                                                                 Activation: N/A\                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                 Leukocytes: N/A                                                                                                                                                                                                                                                                                                                                                                                                                          

  Hermeto 2016 \[[@B38-ijms-19-03322]\]\      Rabbits        AD-MSCs\                            PRP\                                                    Saline vs. PRP vs. undifferentiated MSCs+PRP vs. differentiated MSCs+PRP\                                       Improved tissue repair in both MSCs group at macroscopic and histological examinations; any improvements in PRP alone group                                                                                                                                      
  Genet Mol Res                                              (4 × 10^6^ cells)                   Plt: 997.42 ± 48.01/μL; Activation: 10% Ca gluconate\   Experimental time: 2 months                                                                                                                                                                                                                                                                                                                                                      
                                                                                                 Leukocytes: N/A                                                                                                                                                                                                                                                                                                                                                                                                                          

  Yun 2016 \[[@B39-ijms-19-03322]\]\          Dogs           AD-MSCs\                            PRP\                                                    Saline vs. PRP vs. MSCs+saline vs. MSCs+PRP\                                                                    Decreased lameness score at 2 and at 3 months in both PRP alone and MSCs+PRP groups; significant increases in focal compressive strength in all treatments groups with highest value in MSCs+PRP group; inflammation reduction in both PRP and MSCs+PRP groups   
  J Orthop Surg Res                                          (10^7^ cells)                       Plts: 10^6^/μL\                                         Experimental time: 2, 3, 4 months                                                                                                                                                                                                                                                                                                                                                
                                                                                                 Activation: N/A\                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                 Leukocytes: N/A                                                                                                                                                                                                                                                                                                                                                                                                                          

  Mifune 2013 \[[@B37-ijms-19-03322]\]\       Rats           MDSCs\                              PRP\                                                    Saline vs. PRP vs. MDSCs vs. MDSCs expressing BMP-4/sFlt1+PRP vs. MDSCs expressing BMP-4/sFlt1 vs. MDSCs+PRP\   Significant AC repair at histology in MDSCs expressing BMP-4/sFlt1+ PRP at 4 weeks compared with MDSCs expressing BMP-4/sFlt1, with higher numbers of cells producing type-II collagen and lower levels of chondrocyte apoptosis                                 
  Osteoarthritis Cartilage                                   (5 × 10^5^ cells)                   Plts: 230 × 10^4^/mL)\                                  Experimental time: 4 and 12 weeks                                                                                                                                                                                                                                                                                                                                                
                                                                                                 Activation: N/A\                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                 Leukocytes: N/A                                                                                                                                                                                                                                                                                                                                                                                                                          

  **HA**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Kim 2012 \[[@B43-ijms-19-03322]\]\          Rabbits        Osteochondral defect                BMSCs\                                                  HA                                                                                                              No treatment vs. HA vs. MSCs vs. MSCs+HA vs. MSCs+HA inj vs. MSCs+HA+1 HA inj vs. MSCs+HA+2 HA inj\                                                                                                                                                              Significant improvements in osteochondral defect healing at macroscopic and histological evaluation in all treatment groups compared with untreated defects; at histology, MSCs+HA+2 HA inj showed better results than other groups
  Knee Surg Relat Res                                                                            (10^6^ cells)                                                                                                                                                           Experimental time: 7 weeks                                                                                                                                                                                                                                       

  McIlwraith 2011 \[[@B42-ijms-19-03322]\]\   Horses         BMSCs\                              High molecular weight HA                                MFX+HA or MFX+HA+MSCs Experimental time: 6 and 12 months                                                        No difference in clinical and histological analysis, but significant increase in repair tissue firmness and better repair tissue quality at arthroscopic and macroscopic analysis in MSCs group with greater levels of aggrecan than in HA alone group           
  Arthroscopy                                                (20 × 10^6^ cells)                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Saw 2009 \[[@B41-ijms-19-03322]\]\          Goats          BMC                                 High molecular weight HA                                No treatment vs. subchondral drilling + 3 HA inj vs. subchondral drilling + 3 HA + BMC inj\                     Better cartilage repair in MSCs group at histology, with hyaline cartilage regeneration                                                                                                                                                                          
  Arthroscopy                                                                                                                                            Experimental time: 24 weeks                                                                                                                                                                                                                                                                                                                                                      

  Lee 2007 \[[@B40-ijms-19-03322]\]\          Minipigs       BMSCs\                              High molecular weight HA                                Saline vs. HA vs. MSCs+HA\                                                                                      Improvement in cartilage healing at histologic and macroscopic analysis at both 6 and 12 weeks in MSCs+HA group compared with controls                                                                                                                           
  Stem Cells                                                 (3.5--10.1 × 10^6^ cells)                                                                   Experimental time: 6 and 12 weeks                                                                                                                                                                                                                                                                                                                                                

  Lv 2018 \[[@B46-ijms-19-03322]\]\           Sheep          OA                                  SVF vs. cultured AD-MSCs                                Medium molecular weight HA                                                                                      Saline vs. HA vs. SVF/HA vs. low dose AD-MSCs/HA vs. high dose AD-MSCs/HA\                                                                                                                                                                                       Better results in AD-MSCs/HA than SVF/HA in blocking OA progression and promoting cartilage regeneration
  Cell Transplant                                                                                                                                                                                                                                                        Experimental time:                                                                                                                                                                                                                                               

  Feng 2017 \[[@B45-ijms-19-03322]\]\         Sheep          Allogeneic AD-MSCs\                 Medium molecular weight HA                              High dosage AD-MSCs or low dosage + HA vs. HA alone vs. saline\                                                 Typical articular cartilage feature in both AD-MSCs groups and presence of AD-MSCs at synovium at 14 weeks at MRI; lower inflammatory factors from synovial fluid of AD-MSCs groups than HA alone                                                                
  Tissue Eng Part A                                          (5 × 10^7^ cells vs. 10^7^ cells)                                                           Experimental time: 14 weeks                                                                                                                                                                                                                                                                                                                                                      

  Desando 2017 \[[@B34-ijms-19-03322]\]\      Rabbits        BMSCs (2 × 10^6^ cells) and BMC     High molecular weight HA                                BMSCs+saline vs. BMSCs+HA vs. BMC+saline vs. BMC+HA\                                                            Joint repair evidence in all treatments, superior results for BMC-HA than other groups; BMSCs migrate to the meniscus while BMC in cartilage, but HA favor cells migration to cartilage                                                                          
  Tissue Eng Part C                                                                                                                                      Experimental time: 2 months                                                                                                                                                                                                                                                                                                                                                      

  Chiang 2016 \[[@B49-ijms-19-03322]\]\       Rabbits        Allogeneic BMSCs\                   High molecular weight HA                                Untreated vs. Sham vs. HA vs. MSCs+HA\                                                                          Less cartilage loss and surface abrasion with better histological scores and cartilage content in MSCs group compared with HA alone; engraftment of allogenic MSCs were evident in surface cartilage                                                             
  Plos ONE                                                   (10^6^ cells)                                                                               Experimental time: 6 and 12 weeks                                                                                                                                                                                                                                                                                                                                                

  Suhaeb 2012 \[[@B50-ijms-19-03322]\]\       Rat            BMSCs\                              High molecular weight HA                                HA vs. BMSCs vs. BMSCs+HA                                                                                       Better results with HA and BMSCs alone in counteracting OA progression with respect to their combination                                                                                                                                                         
  Indian J Exp Biol                                          (3-5 × 10^6^ cells)                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Sato 2012 \[[@B48-ijms-19-03322]\]\         Pigs           Xenogeneic hMSCs\                   Low molecular weight HA                                 Saline vs. HA vs. MSCs+saline vs. MSCs+HA\                                                                      Histological partial defect repair only in MSCs+HA group at 5 weeks with an increase in type-II collagen content and low levels of MMP-13                                                                                                                        
  Arthritis Res Ther                                         (7 × 10^6^ cells)                                                                           Experimental time: 5 weeks                                                                                                                                                                                                                                                                                                                                                       

  Mokbel 2011 \[[@B47-ijms-19-03322]\]\       Donkeys        BMSCs\                              Low molecular weight HA                                 MSCs+HA vs. HA alone\                                                                                           Defect repair at clinical and radiological evaluation in MSCs+HA group compared with the control; MSCs integrated with healthy cartilage in the superficial and inner part                                                                                       
  BMC Musculoskeletal Disorders                              (1.8-2.3 × 10^6^ cells/mL)                                                                  Experimental time: 1, 2, 6 months                                                                                                                                                                                                                                                                                                                                                

  Murphy 2003 \[[@B44-ijms-19-03322]\]\       Goats          BMSCs\                              High molecular weight HA                                HA vs. HA+BMSCs\                                                                                                No adverse events; stimulation of the regeneration of meniscal tissue and delay of OA progression in MSCs group                                                                                                                                                  
  Arthritis Rheum                                            (10 × 10^6^ cells)                                                                          Experimental time: 12 and 26 weeks                                                                                                                                                                                                                                                                                                                                               

  **Hydrogel**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Kim 2016 \[[@B51-ijms-19-03322]\]\          Rat OA         OA                                  PBMSCs                                                  SAP hydrogel                                                                                                    SAP hydrogel 0.5 SP vs. SAP hydrogel SP vs. SAP hydrogel 2SP vs. SAP hydrogel SP+MSCs\                                                                                                                                                                           Markedly improved cartilage regeneration in the SAP-SP group showing recruitment of MSCs in the defect
  Biomaterials                                                                                                                                                                                                                                                           Experimental time: 6 weeks                                                                                                                                                                                                                                       

  Kim 2014 \[[@B52-ijms-19-03322]\]\          Rat OA         Allogeneic BMSCs                    SAP hydrogel                                            MSCs vs. SAP hydrogel vs. SAP hydrogel+MSCs vs. no treatment\                                                   Evidence of chondroprotection at histological view and decrease of inflammation and apoptosis biomarkers in SAP+MSCs group; increased BMD in SAP hydrogel+MSCs groups relative to the controls                                                                   
  Int J Nanomed                                                                                                                                          Experimental time: 6 weeks                                                                                                                                                                                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** adipose-derived mesenchymal stromal cells, AD-MSCs; articular cartilage, AC; hyaluronic acid, HA; magnetic resonance imaging, MRI; platelet rich plasma, PRP; degenerative joint disease, DJD; peripheral blood MSCs, PBMSCs; self-assembled peptide, SAP; substance P, SP; bone marrow concentrate, BMC; bone marrow-derived MSCs, BMSCs (cultured); matrix metalloproteinase, MMP; muscle-derived MSCs, MDSCs; human umbilical cord blood MSCs, hUCB-MSCs; extracellular matrix, ECM; microfracture MFX; bone mineral density, BMD; stromal vascular fraction, SVF.
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Details of clinical papers identified in the systematic research.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Defect type                               Publication                               Study Type       MSC Type                       Delivery System                                                                  Study Design                                                                                                                                                       Results
  ----------------------------------------- ----------------------------------------- ---------------- ------------------------------ -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------
  **PRP**                                                                                                                                                                                                                                                                                                                                                                                 

  Osteochondral lesion                      Kim 2015 \[[@B53-ijms-19-03322]\]\        Comparative      SVF                            PRP\                                                                             40 pts (20 vs. 20) (knee)\                                                                                                                                         Significant improvement in both groups; better clinical results at final follow-up and 2nd look appearance at 12 months for SVF-FG
                                            Am J Sports Med                                                                           Plts: 1.28 × 10^6^/μL\                                                           Age: mean 59.2 years\                                                                                                                                              
                                                                                                                                      Activation: CaCl~2~\                                                             Lesion size/degree: 5.44 ± 1.4 cm^2^\                                                                                                                              
                                                                                                                                      Leukocytes: N/A                                                                  Treatment: SVF on FG scaffold vs. SVF+PRP\                                                                                                                         
                                                                                                                                                                                                                       Follow-up: 28.6 months                                                                                                                                             

  OA                                        Bastos 2018 \[[@B54-ijms-19-03322]\]\     RCT              Cultured BMSCs                 PRP\                                                                             18 pts (9 vs. 9) (knee)\                                                                                                                                           Improvement in knee pain and function in both groups, without significance difference
                                            KSSTA                                                                                     Plts: 10^6^/μL\                                                                  Age: mean 57.6 years\                                                                                                                                              
                                                                                                                                      Activation: N/A\                                                                 Lesion size/degree: grade II-IV\                                                                                                                                   
                                                                                                                                      Leukocytes: N/A                                                                  Treatment: BMSCs vs. BMSCs+PRP\                                                                                                                                    
                                                                                                                                                                                                                       Follow-up: 12 months                                                                                                                                               

  Bansal 2017 \[[@B55-ijms-19-03322]\]\     Case series                               SVF              PRP\                           10 pts (knee)\                                                                   Functional improvement with pain reduction at 12 and 24 months; reduction of atypical cells in synovial fluid; unaltered haematological and biochemical analysis   
  J Transl Med                                                                                         Plts: N/A\                     Age: mean 58.4 years\                                                                                                                                                                                                                               
                                                                                                       Activation: N/A\               Lesion size/degree: N/A\                                                                                                                                                                                                                            
                                                                                                       Leukocytes: N/A                Treatment: SVF+PRP\                                                                                                                                                                                                                                 
                                                                                                                                      Follow-up: 3, 6, 12, 18, 24 months                                                                                                                                                                                                                  

  Pintat 2017 \[[@B56-ijms-19-03322]\]\     Case series                               SVF              PRP\                           19 pts (knee)\                                                                   Functional improvement at 6 and 12 month follow-ups with no complications but no relevant changes at MRI                                                           
  J Vasc Interv Radiol                                                                                 Plts: 700,000/mm^3^\           Age: mean 42.1 years\                                                                                                                                                                                                                               
                                                                                                       Activation: N/A\               Lesion size/degree: N/A\                                                                                                                                                                                                                            
                                                                                                       Leukocytes: 200/mm^3^          Treatment: SVF+PRP\                                                                                                                                                                                                                                 
                                                                                                                                      Follow-up: 6 and 12 months                                                                                                                                                                                                                          

  Shapiro 2017 \[[@B57-ijms-19-03322]\]\    RCT                                       BMAC             PPP                            25 pts (knee)\                                                                   No adverse events; similar pain relief in both group                                                                                                               
  Am J Sports Med                                                                                                                     Age: mean 60 years\                                                                                                                                                                                                                                 
                                                                                                                                      Lesion size/degree: 2.3 K-L\                                                                                                                                                                                                                        
                                                                                                                                      Treatment: BMC+PPP vs. saline\                                                                                                                                                                                                                      
                                                                                                                                      Follow-up: 6 months                                                                                                                                                                                                                                 

  Gibbs 2015 \[[@B58-ijms-19-03322]\]\      Case series                               SVF              PRP\                           4 pts (7 knees)\                                                                 Functional, pain and quality of life score improvement at 12 months                                                                                                
  J Pain Res                                                                                           Plts: N/A\                     Age: mean 51.5 years\                                                                                                                                                                                                                               
                                                                                                       Activation: N/A\               Lesion size/degree: N/A\                                                                                                                                                                                                                            
                                                                                                       Leucocytes: N/A                Treatment: SVF+PRP and 3 monthly PRP inj\                                                                                                                                                                                                           
                                                                                                                                      Follow-up: 12 months                                                                                                                                                                                                                                

  Srinivas 2015 \[[@B59-ijms-19-03322]\]\   Case series                               BMC              PRP\                           115 pts (knee)\                                                                  Pain improvement from 1 week up to 6 months after injection of PRP + BMC                                                                                           
  J of evolution of med and Dent Sci                                                                   Plts: N/A\                     Age: 56--87 years\                                                                                                                                                                                                                                  
                                                                                                       Activation: N/A\               Lesion size/degree: moderate to severe\                                                                                                                                                                                                             
                                                                                                       Leucocytes: N/A                Treatment: 65 BMC+PRP and 50 corticosteroid\                                                                                                                                                                                                        
                                                                                                                                      Follow-up: 6 months                                                                                                                                                                                                                                 

  Koh 2015 \[[@B60-ijms-19-03322]\]\        Case series                               SVF              PRP\                           30 pts (knee)\                                                                   Significant clinical improvement; 87.5% of 2nd look arthroscopy within 24 months improved or maintained cartilage status                                           
  KSSTA                                                                                                Plts: 1.28 × 10^6^ cells/μL\   Age: mean 70.3 years\                                                                                                                                                                                                                               
                                                                                                       Activation: N/A\               Lesion size/degree: 2.3 K-L\                                                                                                                                                                                                                        
                                                                                                       Leucocytes: N/A                Treatment: SVF+PRP\                                                                                                                                                                                                                                 
                                                                                                                                      Follow-up: 24 months                                                                                                                                                                                                                                

  Pham 2014 \[[@B61-ijms-19-03322]\]\       Case series                               SVF              PRP\                           21 pts (knee)\                                                                   Significant clinical scores improvement; no side effects; increased cartilage thickness at MRI                                                                     
  Biomed Res Ther                                                                                      Plts: N/A\                     Age: N/A\                                                                                                                                                                                                                                           
                                                                                                       Activation: CaCl~2~\           Lesion size/degree: II/III\                                                                                                                                                                                                                         
                                                                                                       Leukocytes: N/A                Treatment: SVF+PRP\                                                                                                                                                                                                                                 
                                                                                                                                      Follow-up: 6 months                                                                                                                                                                                                                                 

  Koh 2014 \[[@B62-ijms-19-03322]\]\        RCT                                       SVF              PRP\                           44 pts (21 vs. 23) (knee)\                                                       Better improvement of KOOS pain and symptoms and VAS pain in SVF+PRP than PRP alone                                                                                
  Arthroscopy                                                                                          Plts: 1.303 × 10^3^ mL\        Age: mean 53.2 years\                                                                                                                                                                                                                               
                                                                                                       Activation: N/A\               Lesion size/degree: 1--3 K--L\                                                                                                                                                                                                                      
                                                                                                       Leukocytes: N/A                Treatment: HTO+PRP vs. HTO+PRP+SVF\                                                                                                                                                                                                                 
                                                                                                                                      Follow-up: 24 months                                                                                                                                                                                                                                

  Kim 2013 \[[@B63-ijms-19-03322]\]\        Comparative                               SVF              PRP\                           75 pts (ankle)\                                                                  Clinical improvement in both groups with better results for SVF group                                                                                              
  Am J Sports Med                                                                                      Plts: N/A\                     Age: mean 56.8 years\                                                                                                                                                                                                                               
                                                                                                       Activation: N/A\               Lesion size/degree: 108.76 ± 34.6 mm^2^\                                                                                                                                                                                                            
                                                                                                       Leukocytes: N/A                Treatment: MFX vs. MFX+SVF+PRP\                                                                                                                                                                                                                     
                                                                                                                                      Follow-up: 21.8 months                                                                                                                                                                                                                              

  Koh 2013 \[[@B64-ijms-19-03322]\]\        Case series                               SVF              PRP\                           18 pts (knee)\                                                                   Function and pain improvement\                                                                                                                                     
  Arthroscopy                                                                                          Plts: 1.28 × 10^6^/μL\         Age: mean 54.6\                                                                  WOMAC and MRI correlate with cell numbers, better if OA \< 3                                                                                                       
                                                                                                       Activation: CaCl~2~\           Lesion size/degree: ICRS grade 3 or 4\                                                                                                                                                                                                              
                                                                                                       Leukocytes: N/A                Treatment: SVF+PRP\                                                                                                                                                                                                                                 
                                                                                                                                      Follow-up: 24.3 months                                                                                                                                                                                                                              

  Koh 2012 \[[@B65-ijms-19-03322]\]\        Comparative                               SVF              PRP\                           50 pts (knee)\                                                                   No major adverse events; improvement of clinical scores in both groups; SVF performed better at \< 55 years and OA \< 3                                            
  Knee                                                                                                 Plts: 1.28 × 10^6^/μL\         Age mean: N/A\                                                                                                                                                                                                                                      
                                                                                                       Activation: CaCl~2~\           Lesion size/degree: ICRS grade mean 3.2\                                                                                                                                                                                                            
                                                                                                       Leukocytes: N/A                Treatment: debridement vs. debridement+SVF+PRP+2 weekly PRP inj\                                                                                                                                                                                    
                                                                                                                                      Follow-up: 16.4 months                                                                                                                                                                                                                              

  **HA**                                                                                                                                                                                                                                                                                                                                                                                  

  Chondral lesion                           Saw 2013 \[[@B66-ijms-19-03322]\]\        RCT              PBPCs                          High molecular weight HA                                                         50 pts (25 vs. 25) (knee)\                                                                                                                                         Improvement of the quality of articular cartilage repair in PBSC group at histologic and MRI evaluation
                                            Arthroscopy                                                                                                                                                                Age: mean 40 years\                                                                                                                                                
                                                                                                                                                                                                                       Lesions size: ICRS grade 3 and 4 lesions\                                                                                                                          
                                                                                                                                                                                                                       Treatment: Subchondral drilling + 5 weekly inj of PBPCs+HA vs. HA alone+3 weekly inj after 6 months\                                                               
                                                                                                                                                                                                                       Follow-up: from 18 to 24 months                                                                                                                                    

  Lee 2012 \[[@B67-ijms-19-03322]\]\        Comparative                               Cultured BMSCs   High molecular weight HA       70 (35 vs. 35) (knee)\                                                           No significant difference between the two procedures, with less invasivity for BMSCs/HA IA inj                                                                     
  Ann Accad Med                                                                                                                       Age: mean 44\                                                                                                                                                                                                                                       
                                                                                                                                      Lesion size: N/A\                                                                                                                                                                                                                                   
                                                                                                                                      Treatment: MFX+inj of BMSCs+HA (+ 2 weekly inj HA) vs. BMSCs+periosteal patch\                                                                                                                                                                      
                                                                                                                                      Follow-up: 24.5 months                                                                                                                                                                                                                              

  Saw 2011 \[[@B68-ijms-19-03322]\]\        Case series                               PBPCs            High molecular weight HA       5 pts (knee)\                                                                    No adverse events; hyaline cartilage regeneration at histology                                                                                                     
  Arthroscopy                                                                                                                         Age: mean 39.4 years\                                                                                                                                                                                                                               
                                                                                                                                      Lesions size: 2 grade IV kissing lesions--3 small\                                                                                                                                                                                                  
                                                                                                                                      Treatment: Subchondral drilling+PBPCs+HA 5 weekly inj\                                                                                                                                                                                              
                                                                                                                                      Follow-up: from 10 to 26 months                                                                                                                                                                                                                     

  OA                                        Wong 2013 \[[@B69-ijms-19-03322]\]\       RCT              Cultured BMSCs                 N/A                                                                              56 pts (28 vs. 28) (knee)\                                                                                                                                         Clinical improvement at short term and MOCART outcomes at 1 year in cells group
                                            Arthroscopy                                                                                                                                                                Age mean: mean 51 years\                                                                                                                                           
                                                                                                                                                                                                                       Lesion size/degree:\                                                                                                                                               
                                                                                                                                                                                                                       Treatment: BMSCs+HA vs. HA inj after MFX+HTO\                                                                                                                      
                                                                                                                                                                                                                       Follow-up: 24 months                                                                                                                                               

  **Combination of delivery agents**                                                                                                                                                                                                                                                                                                                                                      

  OA                                        Turajane 2017 \[[@B70-ijms-19-03322]\]\   RCT              AAPBSCs                        PRP\                                                                             60 pts (20 vs. 20 vs. 20)\                                                                                                                                         Avoidance of TKA in the AAPBSC groups at 12 months and potent, early, and sustained symptom alleviation in GFA groups vs. HA alone
                                            Stem Cells Int                                                                            Plts: N/A\                                                                       Age: mean 56.5 years\                                                                                                                                              
                                                                                                                                      Activation: N/A\                                                                 Lesion size/degree: 2.3 K-L\                                                                                                                                       
                                                                                                                                      Leukocytes: N/A\                                                                 Treatment: MFX + 3 weekly inj of AAPBSCs+HA+PRP+hGCSF vs. MFX+3 weekly inj of AAPBSCs+HA+PRP vs. 3 weekly inj HA alone\                                            
                                                                                                                                      High molecular weight HA                                                         Follow-up: 12 months                                                                                                                                               

  Pak 2016 \[[@B71-ijms-19-03322]\]\        Case series                               SVF              PRP\                           3 pts (knee)\                                                                    Function and pain improvement at 3 months with signs of regenerating cartilage-like tissue at MRI                                                                  
  BioRes Open Access                                                                                   Plts: N/A\                     Age: mean 71.6 years\                                                                                                                                                                                                                               
                                                                                                       Activation: CaCl~2~\           Lesion size/degree: stage 3 OA\                                                                                                                                                                                                                     
                                                                                                       Leukocytes: N/A                Treatment: SVF+PRP+HA+3 weekly PRP inj\                                                                                                                                                                                                             
                                                                                                                                      Follow-up: 3 months                                                                                                                                                                                                                                 

  Pak 2013 \[[@B72-ijms-19-03322]\]\        Case series                               SVF              PRP\                           91 pts (various anatomic locations)\                                             SVF/PRP injections are safe; clinical improvement of knee and hip                                                                                                  
  BMC Musculoskeletal Disord                                                                           Plts: N/A\                     Age: mean 51.23 years\                                                                                                                                                                                                                              
                                                                                                       Activation: CaCl~2~\           Lesion size/degree: N/A\                                                                                                                                                                                                                            
                                                                                                       Leukocytes: N/A                Treatment: SVF+PRP+HA+4 weekly PRP inj\                                                                                                                                                                                                             
                                                                                                                                      Follow-up: 26.62 months                                                                                                                                                                                                                             

  Pak 2011 \[[@B73-ijms-19-03322]\]\        Case report                               SVF              PRP\                           2 pts (knee), 2 pts (hip)\                                                       Clinical improvement; significant positive changes at MRI                                                                                                          
  J Med Case Rep                                                                                       Plts: N/A\                     Age: 70, 79, and 29, 47 years\                                                                                                                                                                                                                      
                                                                                                       Activation: CaCl~2~\           Lesion size/degree: N/A\                                                                                                                                                                                                                            
                                                                                                       Leukocytes: N/A                Treatment: SVF+PRP+low dose\                                                                                                                                                                                                                        
                                                                                                                                      dexamethasone inj\                                                                                                                                                                                                                                  
                                                                                                                                      Follow-up: 3 months                                                                                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** peripheral blood progenitor cells, PBPCs; hyaluronic acid, HA; randomized controlled trial, RCT; not available, N/A; fibrin glue, FG; bone marrow aspirate concentrate, BMAC; high tibial osteotomy, HTO; microfracture, MFX; bone marrow concentrate, BMC; platelet poor plasma, PPP; autologous activated peripheral blood stem cells, AAPBSCs; bone marrow-derived mesenchymal stromal cells, BMSCs; stromal vascular fraction, SVF.
